Hoyt R E
South Med J. 1987 Sep;80(9):1196-7. doi: 10.1097/00007611-198708090-00032.
With increased use of sustained-release forms of procainamide in treating common cardiac arrhythmias, more and more cases of severe neutropenia and occasional deaths have been reported. It is unclear whether all sustained-release procainamide preparations are implicated. I recommend that a complete blood count be done every two weeks for the first three months of treatment with these drugs. Any patient who has an unexplained fever or a toxic reaction while taking one of these preparations should have a complete blood count done.
随着普鲁卡因胺缓释剂型在治疗常见心律失常中的使用增加，越来越多严重中性粒细胞减少症病例及偶发死亡病例被报道。目前尚不清楚是否所有普鲁卡因胺缓释制剂都与此有关。我建议在使用这些药物治疗的前三个月，每两周进行一次全血细胞计数。任何在服用这些制剂之一时出现不明原因发热或毒性反应的患者都应进行全血细胞计数检查。
